Esperion Therapeutics Stock News

Esperion's (ESPR) stock rallies so far this year on higher product sales in the fourth quarter of 2021. Cost-saving initiatives to boost margins in 2022 are another key drivers.

The commercial-stage pharma company, Esperion Therapeutics (ESPR) announced on Tuesday that the company’s Chief Financial Officer Richard B

Gainers: Incannex Healthcare Limited IXHL +271%. Esperion Therapeutics (ESPR) +10%

H.C. Wainwright has started the coverage on Esperion Therapeutics <> with a Buy recommendation on Thursday, citing the commercial-stage pharma company’s lead products…

Esperion Therapeutics recently reported their Q4 and full-year 2021 earnings. NEXLETOL and NEXLIZET together secured $12.2M in U.S. net product revenue, which is up 200% for the year.

Gainers Imperial Petroleum Inc. (NASDAQ: IMPP ) jumped 63.1% to close at $0.80 on Tuesday after declining around 7% on Friday. Indonesia Energy Corporation Limited (NYSE: INDO ) shares surged 44.1% to close at $6.47 on Tuesday. Meritor, Inc. (NYSE: MTOR ) shares climbed 43.8% to settle at $35.47. Cummins Inc (NYSE: CMI ) agreed to acquire electric powertrain solutions provider Meritor for about $3.7 billion, including assumed debt and net of acquired cash. China Natural Resources, Inc. (NASDAQ: CHNR ) surged 27.4% to close at $0.7901. Paltalk, Inc. (NASDAQ: PALT ) rose 26.1% to close at $3.96. Ocugen, Inc. (NASDAQ: OCGN ) gained 22.3% to close at $4.23. The FDA has lifted its clinical hold on Ocugens investigational new drug application seeking approval to conduct testing of the COVID-19 vaccine Covaxin in the U.S. Arteris, Inc. (NASDAQ: AIP ) climbed 19% to close at $17.83. Arteris is expected release its financial results for the fourth quarter on Thursday, March 3, 2022. SeaChange International, Inc. (NYSE: SEAC ) rose 18.9% to settle at $1.26.

ESPR earnings call for the period ending December 31, 2021.

Esperion Therapeutics, Inc. (ESPR) CEO Sheldon Koenig on Q4 2021 Results - Earnings Call Transcript

Esperion Therapeutics (NASDAQ: ESPR ) reported its Q4 earnings results on Tuesday, February 22, 2022 at 07:00 AM. Here''s what investors need to know about the announcement. Earnings Esperion Therapeutics beat estimated earnings by 22.03%, reporting an EPS of $-1.77 versus Full story available on Benzinga.com

Esperion Therapeutics press release (ESPR): Q4 GAAP EPS of -$1.77 beats by $0.52.Revenue of $15.4M (+59.8% Y/Y) beats by $0.92M.As of December 31, 2021, cash, cash

Esperion Therapeutics (ESPR) delivered earnings and revenue surprises of 23.71% and 6.21%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock

Companies Reporting Before The Bell Gaotu Techedu (NYSE: GOTU ) is projected to report quarterly earnings at $0.13 per share on revenue of $439.63 million. Sohu.com (NASDAQ: SOHU ) is expected to report earnings for its fourth quarter. Kiniksa Pharmaceuticals (NASDAQ: KNSA ) is likely to report quarterly loss at $0.42 per share on revenue of $20.72 million. Hecla Mining (NYSE: HL ) is expected to report quarterly earnings at $0.02 per share on revenue of $198.95 million. Standard Motor Products (NYSE: SMP ) is expected to report quarterly earnings at $0.67 per share on revenue of $282.91 million. KBR (NYSE: KBR ) is likely to report quarterly earnings at $0.65 per share on revenue of $2.53 billion. Fresenius Medical Care (NYSE: FMS ) is likely to report quarterly earnings at $0.49 per share on revenue of $5.22 billion. Ardagh Metal Packaging (NYSE: AMBP ) is expected to report quarterly earnings at $0.09 per share on revenue of $1.02 billion. Krispy Kreme (NASDAQ: DNUT ) is estimated to report quarterly earnings at $0.

Esperion Therapeutics (NASDAQ:ESPR) is scheduled to announce Q4 earnings results on Tuesday, February 22nd, before market open.The consensus EPS Estimate is -$2.29 and the consensus…